📊 Stock Detail Analysis

Grifols, S.A. (GRFS)

Discovery Date: 2026-07-20 | Base Price: 7.61

Current Price: 7.72 (+1.45%)

✅ Key Stock Summary

Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines. The company has reported mixed recent performance, reflecting both challenges and opportunities in the market. With a current share price of $7.61, the valuation indicates a notable basis point differential.

✅ Stock Information

Grifols, S.A. is a leader in the biopharmaceutical industry, focusing on the research, development, and production of plasma-derived therapies. Recent earnings reports have shown a blend of revenue growth alongside increased operational costs, leading to a cautious outlook. The company's share price has experienced fluctuations, currently standing at $7.61, which suggests a significant basis point of 164389 compared to its intrinsic value. Investors are weighing the company's solid market position against broader economic pressures and competition. The company continues to invest in R&D, aiming to expand its product offerings and market reach.

📰 Related News

Grifols reports mixed earnings, shares fluctuate

Earnings report affected investor sentiment.

Plasma prices increase, impacting Grifols' margins

Cost pressures may influence future profitability.

New product line announced, aiming for market expansion

Potential for revenue growth in upcoming quarters.

🏭 Competitor Comparison

CSL Behring (CSLLY)

CSL Behring is a strong competitor in the plasma-derived therapies market, often leading in innovation.

Octapharma (OCTHF)

Octapharma focuses on similar product lines, but with a more aggressive pricing strategy.

Kedrion Biopharma (KEDRI)

Kedrion offers a more niche selection of plasma products, catering to specific therapeutic areas.